Identification of novel N-benzyloxy-amino acid hydroxamates as inhibitors of the virulence factor LasB from Pseudomonas aeruginosa
- RSC Med Chem. 2025 Aug 13. doi: 10.1039/d5md00393h.
- 1. Department of Pharmacy, University of Pisa via Bonanno 6 56126 Pisa Italy [email protected] +39 0502219551.
- 2. Institute of Clinical Physiology, National Research Council (CNR) via Moruzzi 1 56124 Pisa Italy.
- 3. Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa Via S. Zeno 37-39 56123 Pisa Italy.
- 4. Department of Medical Biology, Faculty of Health Sciences, UiT-The Arctic University of Norway NO-9037 Tromsø Norway.
- 5. Center for Research and Education, University Hospital of North Norway (UNN) Norway.
The emergence of multidrug-resistant pathogens, particularly Pseudomonas aeruginosa, represents a global health concern. Among its major virulence factors, Elastase B (LasB), a zinc-dependent metalloprotease, plays a pivotal role in host tissue degradation, immune evasion, and biofilm formation. Targeting LasB with selective inhibitors offers a promising therapeutic strategy to mitigate Bacterial virulence while minimizing selective pressure for resistance development. In this study, a series of N-benzyloxy Amino Acid Derivatives were designed, synthesized, and evaluated for their inhibitory activity against LasB. Structure-based optimization led to the identification of compound 12 as the most potent inhibitor (K i = 0.92 μM), exhibiting high selectivity for LasB over human Matrix Metalloproteinases. Cell-based assays demonstrated its ability to inhibit LasB proteolytic activity and reduce biofilm formation without affecting Bacterial viability. These findings highlight the potential of LasB inhibitors as pathoblockers, providing a targeted approach to disarm Bacterial virulence rather than exerting bactericidal pressure.